PET/CT Scans | NYU Langone Health
NYU Langone offers PET/CT scans to diagnose illness, evaluate treatments, and assess recurrences of many conditions, including cancer.
Phase 1 Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor) Alone and in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer
This is a multicenter, open-label Phase 1 study in participants with metastatic castration-resistant prostate cancer (mCRPC) to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of KTX-2001 monotherapy (Part A) and KTX-2001 in combination with darolutamide 600 mg twice daily (BID) (Part B), and to establish a recommended Phase 2 dose(s) of KTX-2001 for future study.
Phase 1 study of intratumoral administration of JNJ-87704916 an oncolytic virus as monotherapy and in combination for advanced solid tumors
This is a phase 1 study, testing the study medicine JNJ-87704916 (an oncolytic herpes simplex virus type 1, HSV-1) alone or in combination with another medicine, cetrelimab (a PD-1 antibody), in patients with advanced solid tumors. This study has two parts. In part 1 of the study, the study team will gradually increase the dose of the study medicine to find out the most effective dose that works well with fewer side effects. In part two, the patients will be divided into two groups. Group A will include patients whose lung cancer has spread from the primary location and the tumor has no PDL-1 expression (PD-L1
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, andPreliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
This is a Phase 1/2 study testing a new drug called mRNA-4359 in people who have solid tumors: a type of cancer that can be measured, has gotten worse, or has spread to other parts of the body. The study will look at how safe mRNA-4359 is, how well people can tolerate it, and what the highest safe dose is when given alone or with other cancer treatments that boost the immune system. Adding a PD-1 inhibitor, like pembrolizumab or nivolumab, to mRNA-4359 might help the body’s immune system fight cancer better. This combination could work better at controlling the disease than just using one of the treatments by itself. Patients will be divided into different groups (called arms) based on what type of cancer they have, whether they have tried other treatments and how much PD-L1 protein their cancer has. Arm 1a will test different doses of mRNA-4359 in patients with advanced or metastatic cancer. Arm 1b will include patients with advanced melanoma or lung cancer that did not respond to other treatments. They will be given a combination of mRNA-4359 and pembrolizumab to determine what dose works best. Arm 2a will include patients with advanced melanoma who have not had any other treatments yet. They will be given both mRNA-4359 and pembrolizumab. Arm 2b will include both mRNA-4359 and pembrolizumab in adults with advanced lung cancer (NSCLC) who have have not had any other treatments for their cancer. Arm 2c will treat adults with advanced melanoma using mRNA-4359 along with two other treatments: ipilimumab and nivolumab. Arm 2d will include patients 12 years or older with advanced melanoma that did not respond to previous treatments, using mRNA-4359 and pembrolizumab. They must have had at least one treatment that did not work before and also their PD-L1 score must be 1% or higher. All patients will have frequent medical check ups and blood samples taken to see how their bodies are handling the study medicine. The study team will have special scans done for all patients to see how the cancer is responding to the study medicines. The study team will be monitoring the patients for potential side effects and safety concerns.
Phase 1/2 Study of PARG Inhibitor ETX-19477 in Patients with Advanced Solid Malignancies
This study is designed to test how the drug moves through the body (pharmacokinetics), how it works (pharmacodynamics), and how well it fights tumors. The drug being tested is ETX-19477, which targets a specific protein in cancer cells. The study has two parts: Phase 1 will test different doses of the drug to find the dose with the least amount of side effects that works, and Phase 2 will look at how well that dose works for treating cancer. In Phase 1, patients will be given different amounts of the drug to see which dose is best tolerated, starting with small doses and increasing them if it’s safe. Researchers will keep track of patients’ health and any side effects, and check how well the drug helps shrink the tumors. The goal is to find the best dose and learn how well ETX-19477 works against advanced cancers.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2)-negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drugconjugates and/or chemotherapy (TRACY-1)
This is a phase 1b/2 study testing whether the study medicine RYZ101 (targeted radiopharmaceutical therapy) will be a safe and better option for treating patients with ER+, HER2-negative breast cancer. This study will be done in two parts. In the first part, patients will be sequentially enrolled and divided into groups to receive study medicine at different dose levels. The study team will find out the dose that works well and has fewer side effects. In the second part of the study, more patients will be included to receive the study medicine that was effective and had fewer side effects for patients in the first part. All patients will have blood samples taken to see how their bodies are handling the study medicine. Special scans will be taken for all patients to see how the study medicine is changing their cancer. The study team will monitor all patients for side effects and safety.
Phase 2/3 Multistage Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The purpose of this study is to see if nipocalimab is safe and useful for treating participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This is the first study where nipocalimab is being administered to participants with CIDP.
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
The primary purpose of the study is to determine if accelerated BEP (Bleomycin, Etoposide, cisPlatin) is effective and tolerable for patients with advanced gem cell tumor compared to the standard treatment. We want to know if the accelerated chemotherapy using the same drugs is beneficial but not more toxic than the standard chemotherapy regimen. The accelerated chemotherapy is experimental.
Phase 3 Randomized Open-label Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
This is a Phase 3 trial testing whether the study medicine sacituzumab tirumotecan (an antibody-drug conjugate, also known as sac-TMT, or MK-2870), when given in combination with another medicine called pembrolizumab (an immunotherapy medicine), is effective and a better treatment in patients with a specific type of endometrial cancer called proficient (pMMR) endometrial cancer. This trial will compare treatment with sac-TMT plus pembrolizumab to pembrolizumab alone. This study has two parts- Part 1 is the Induction phase, where patients will receive pembrolizumab and chemotherapy, and Part 2 is the Maintenance phase, where patients whose cancer has not progressed, as shown by the CT scans, will be divided into two groups to receive either sac-TMT plus pembrolizumab or pembrolizumab alone. Patients will undergo CT scans during the study to see how their cancer is changing in response to the study treatment. Blood samples will be taken from all patients to see how their bodies are handling the study medicine. All patients will be closely monitored for any side effects and safety concerns.